![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
H-100 (nicardipine), a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, is being developed as a topical gel using nanotechnology to potentially enhance permeation of the medication.
Lead Product(s): Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area: Dermatology Product Name: H100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Endo Pharm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
The new partnership, which replaces a previous agreement with Vivus, will transfer manufacturing of the STENDRA (avanafil) tablets, to the United States, and is expected to provide both cost savings and increase in gross margin.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 24, 2022
Details:
Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of Petros Pharmaceuticals' men's health platform including Stendra and for working capital and general corporate purposes.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities LLC
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 30, 2021
Details:
H-100 may be able to provide the first-ever non-invasive treatment to a confounding and often painful condition for which there have been few viable solutions. As a topical, H-100 has the potential to be approved as the first non-invasive treatment for the condition.
Lead Product(s): Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area: Dermatology Product Name: H100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hybrid Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
Details:
Further expanding the partnership, the companies announce the availability of additional dosages of STENDRA in 50mg, 100mg and 200mg tablets, all of which are now accessible through the Hims platform.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hims & Hers Health, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 03, 2021
Details:
Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform which includes enhancing the position of STENDRA, and for working capital and general corporate purposes.
Lead Product(s): Avanafil
Therapeutic Area: Endocrinology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Katalyst Securities
Deal Size: $5.7 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 19, 2021
Details:
Stendra (avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
The Company has initiated a Phase 2 study, which is more significant & Label Comprehension Study that will include low health literacy individuals as part of a multi-step process to develop the behavioral study evidence for FDA to evaluate Stendra for possible OTC designation.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2021